Video

Roswell Park Welcomes New Vice Chair of Clinical Affairs: Dr. Peter Maslak

Peter Maslak, MD, is an expert Hematologic Oncologist, joining Roswell Park as Vice Chair of Clinical Affairs, Director of Flow Cytometry in the Immune Monitoring Shared Resource and the Technical Director of the Flow Cytometry Lab.

Video

Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-Cell Toxicities

Roswell Park Comprehensive Cancer Center pre-doctoral trainee Payal Goala, MS, BS, presented research findings that hold potential to help address two significant toxicities associated with Chimeric Antigen Receptor (CAR) T-cell therapy.

Video

CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan ...

Video

Physician-Scientist Marco Davila, MD, PhD, Joins Growing Roswell Park Cellular Therapy Program

Following a national search, Roswell Park Comprehensive Cancer Center has appointed Marco Davila, MD, PhD, as Senior Vice President and Associate Director for Translational Research and Vice-Chair for Cellular Therapies.

Video

Reaching Deep Remissions with a New Therapy for Multiple Myeloma Patients

Roswell Park is spearheading efforts to study innovative CAR T-cell therapies in addition to offering traditional treatment approaches.

Video

Neurological Effects of Immunotherapy

While immunotherapies are changing the way oncologists treat their patients, these new therapies are not entirely without side effects. Chinazom Ibegbu, MD, Assistant Professor of Oncology and neuro-oncologist at Roswell Park Comprehensive ...

News

Roswell Park Researchers Identify New Biomarker of Response to Checkpoint Inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.

News

Identifying Neurotoxicity Earlier in CAR T-Cell Therapy

At Roswell Park Comprehensive Cancer Center, Philip McCarthy, MD, Director of the Transplant and Cellular Therapy Center in the Department of Medicine, and a multidisciplinary team of colleagues recently undertook a study to understand ...

News

New Roswell Park Strategy for Overcoming Resistance to Immunotherapy Unleashes Power of Dendritic Cells

Many of the most aggressive and hard-to-treat cancers are highly effective at blocking T cells, known as the foot soldiers of the immune system, from reaching and responding to tumors. It’s a cancer defense mechanism that even groundbreaking ...